Royalty Report: Drugs, Cancer, Therapeutic – Collection: 2606


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Delivery
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2606

License Grant
The amendment revised several key financial terms and expanded the Licensed territory to include Japan, thereby granting us the worldwide rights to picoplatin.
License Property
The current major research and development program is picoplatin (NX 473), a new generation platinum therapy designed to overcome platinum resistance in the treatment of solid tumors.  Picoplatin can be used to treat lung, colon and prostrate cancer.

IPSCIO Record ID: 1238

License Grant
The Licensee acquired the rights to develop, manufacture and commercialize picoplatin. In September 2006, we renegotiated the financial terms of our April 2004 License Agreement and obtained exclusive worldwide rights to picoplatin from the Licensor, successor to AnorMED, Inc. Under the License Agreement, as amended, the Licensor retains the right to prosecute its patent applications and maintain all Licensed patents, with the Licensee reimbursing such expenses. If not earlier terminated, the License Agreement will continue in effect, in each country in the territory in which the Licensed product is sold or manufactured, until the earlier of expiration of the last valid claim of a pending or issued patent covering the Licensed product in that country or a specified number of years after first commercial sale of the Licensed product in that country.
License Property
Picoplatin is a new-generation platinum-based chemotherapeutic agent designed to overcome platinum resistance associated with chemotherapy in solid tumors. With respect to picoplatin, the Licensee expects to rely primarily on U.S. Patent No. 5,665,771 (expiring February 7, 2016), which is Licensed to us by the Licensor, and additional Licensed patents expiring in 2016 covering picoplatin in the European Union and other countries. In August 2007, the FDA granted picoplatin Fast Track designation for the second-line treatment of small cell lung cancer.

IPSCIO Record ID: 114493

License Grant
The Company acquired an exclusive, global license of all rights to develop and commercialize Picoplatin.
License Property
Picoplatin is a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.
Field of Use
This agreement pertains to the drug industry relating to integrate a new platinum molecule (Picoplatin) with improved properties into pre-existing pharmaceutical products can improve the success rates of such products, especially because we expect that our technology will allow us to identify prospectively patients that will be more likely to respond positively to the treatment.

IPSCIO Record ID: 26834

License Grant
The licensing agreement that grants exclusive rights to develop, manufacture and commercialise AMD473/NX 473, a platinum-based anticancer agent.
License Property
AMD473/NX 473 has been administered to more than 500 cancer patients in Phase I and II trials, demonstrating anticancer activity in a wide range of tumours and a manageable safety profile.  

The licensee expects to initiate clinical studies of AMD473/NX 473 in one or more cancer indications in the second half of this 2004.  Under the agreement, licensee has acquired an exclusive licence, under a portfolio of issued patents and patent applications, to develop, manufacture and commercialise AMD473/NX 473.  The patent portfolio relates to composition of matter, formulations and methods of use of AMD473/NX 473 and related analogues and compounds, and includes issued patents and patent applications in all major countries.  The agreement also transfers to licensee certain knowledge pertaining to AMD473/NX 473, including clinical and manufacturing data, regulatory submissions and related information.  Also under the agreement, licensor will transfer to licensee an inventory of finished AMD473/NX 473 suitable for use in clinical studies.  In Phase I studies of AMD473/NX 473 as a single agent and in combination with other cancer therapeutics, antitumour activity was observed in a broad range of cancers.  In Phase II monotherapy studies of AMD473/NX 473, objective responses were observed in hormone-resistant prostate cancer, and in second-line ovarian, breast and lung cancers, including platinum-resistant and -sensitive cancers.  Existing platinum agents, such as cisplatin and oxaliplatin, exhibit nephrotoxicity and/or neurotoxicity.  No clinically significant nephrotoxicity or neurotoxicity has been observed with AMD473/NX 473, to date.  Moreover, AMD473/NX 473 has shown oral bioavailability and antitumour activity with oral administration in preclinical studies and has the potential to be the first platinum agent with both intravenous and oral formulations.

IPSCIO Record ID: 114738

License Grant
The Company entered into an assignment of license agreement and an assignment agreement (which is referred to, collectively, as the Assignment Agreement) with Party A.  In 2004 the developer entered into a exclusive worldwide license agreement (Licensors License) with Party B for the development and commercialization of Picoplatin.  Party A acquired this license agreement from Party B on June 30, 2010.  In March 15, 2016 when entering into the Assignment Agreement with Party A, the company also became the assignee of the Licensors license agreement which required the company to pay royalties to the developer.
License Property
Picoplatin is a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.
Field of Use
This agreement pertains to the drug industry relating to cancer therapy.

IPSCIO Record ID: 26619

License Grant
The Licensor hereby grants to the Licensee and its Affiliates a sole and exclusive worldwide sublicense in all fields of use to practice under the Patent Rights and to utilize the Know-how, and to make, have made, use, lease and/or sell the Licensed Products and to practice the Licensed Processes, to the full end of the term for which the Patent Rights are granted, unless sooner terminated as hereinafter provided.
License Property
The Licensor desires to sublicense of such Patent Rights and Know-how in order to commercialize 06-Benzyl guanine (06BG) and related technologies for the treatment of cancer.

O6-Benzylguanine (O6-BG) is a chemosensitizer that is designed to overcome resistance to a significant class of commonly used chemotherapeutic agents known as O6-alkylating agents.  In preclinical animal studies, treatment with O6-BG increased the anti-tumor activity of these agents in brain, colon, and prostate cancers, as well as in melanoma.   A Phase II development program began in 1999.  O6-BG, a series of related compounds and a gene therapy that the Company believes will enhance the effectiveness of a class of currently used chemotherapeutic agents known as O6-alkylating agents.  O6-BG and related compounds are small molecules for intravenous administration in the treatment of cancer.  The Company believes O6-BG to be capable of destroying the resistance of cancer cells to a class of chemotherapeutic agents, O6-alkylating agents.  The Company believes that the effectiveness of alkylating chemotherapeutic agents against various tumors such as brain, prostate, colon cancers, melanoma and lymphoma is limited due to the ability of tumor cells to repair the DNA damage caused by the O6-alkylating agents, because the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT), protects tumor cells by repairing the tumor cell DNA.

The Company believes that O6-BG inactivates the AGT protein in a variety of cancers thereby overcoming resistance to theO6-alkylating agents.

Field of Use
The rights granted apply in all fields of use relating to technologies for the treatment of cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.